JPWO2020068867A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020068867A5 JPWO2020068867A5 JP2021540390A JP2021540390A JPWO2020068867A5 JP WO2020068867 A5 JPWO2020068867 A5 JP WO2020068867A5 JP 2021540390 A JP2021540390 A JP 2021540390A JP 2021540390 A JP2021540390 A JP 2021540390A JP WO2020068867 A5 JPWO2020068867 A5 JP WO2020068867A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- positions
- acid sequence
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736293P | 2018-09-25 | 2018-09-25 | |
| US62/736,293 | 2018-09-25 | ||
| US201962903592P | 2019-09-20 | 2019-09-20 | |
| US62/903,592 | 2019-09-20 | ||
| PCT/US2019/052784 WO2020068867A1 (en) | 2018-09-25 | 2019-09-24 | Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502495A JP2022502495A (ja) | 2022-01-11 |
| JP2022502495A5 JP2022502495A5 (https=) | 2022-10-03 |
| JPWO2020068867A5 true JPWO2020068867A5 (https=) | 2022-10-03 |
Family
ID=68165800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540390A Pending JP2022502495A (ja) | 2018-09-25 | 2019-09-24 | チロシンキナーゼ阻害剤としてのキナゾリン誘導体、組成物、それらの作製方法、およびそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11034672B1 (https=) |
| EP (1) | EP3856726A1 (https=) |
| JP (1) | JP2022502495A (https=) |
| KR (1) | KR20210137422A (https=) |
| CN (1) | CN113382986A (https=) |
| AU (1) | AU2019346550A1 (https=) |
| BR (1) | BR112021005513A2 (https=) |
| CA (1) | CA3113241A1 (https=) |
| IL (1) | IL281805A (https=) |
| MX (1) | MX2021003517A (https=) |
| SG (1) | SG11202102981SA (https=) |
| WO (1) | WO2020068867A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019346550A1 (en) | 2018-09-25 | 2021-04-22 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use |
| EP4013749B1 (en) | 2019-08-15 | 2026-03-11 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| WO2021195206A1 (en) * | 2020-03-24 | 2021-09-30 | Black Diamond Therapeutics, Inc. | Polymorphic forms and related uses |
| AR122450A1 (es) * | 2020-05-08 | 2022-09-14 | Lilly Co Eli | Compuestos de (trifluorometil)pirimidin-2-amina |
| US20230265098A1 (en) * | 2020-07-02 | 2023-08-24 | Enliven Therapeutics, Inc. | Alkyne quinazoline derivatives as inhibitors of erbb2 |
| US20230271936A1 (en) * | 2020-08-10 | 2023-08-31 | Abbisko Therapeutics Co., Ltd | Efgr inhibitor, preparation method therefor and application thereof |
| WO2022040377A1 (en) | 2020-08-20 | 2022-02-24 | Black Diamond Therapeutics, Inc. | Methods for preparing quinazoline derivatives |
| AU2021347232A1 (en) | 2020-09-23 | 2023-04-27 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022076671A1 (en) * | 2020-10-08 | 2022-04-14 | Black Diamond Therapeutics, Inc. | Method of treating cancers using quinazoline derivatives |
| CN116710096A (zh) * | 2020-11-02 | 2023-09-05 | 黑钻治疗公司 | 用炔取代的喹唑啉衍生物治疗癌症的方法 |
| US20240075042A1 (en) * | 2020-11-02 | 2024-03-07 | Black Diamond Therapeutics, Inc. | Method of treating cancers with alkyne substituted quinazoline derivatives |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| CN116655599B (zh) * | 2023-05-17 | 2025-07-29 | 江南大学 | 一类egfr别构抑制剂的合成及其用途 |
| EP4724436A1 (en) * | 2023-06-12 | 2026-04-15 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2025096300A1 (en) * | 2023-10-30 | 2025-05-08 | Eli Lilly And Company | Novel methods for the preparation of 3-azabicylco[3.1,0]hexane-6-carboxamide derivatives |
| CN118084767B (zh) * | 2024-04-02 | 2025-06-17 | 康龙化成手性医药技术(宁波)有限公司 | 一种外型-6-氟甲基-3-氮杂双环[3,1,0]己烷盐酸盐及其衍生物的合成方法 |
| CN118652239A (zh) * | 2024-05-29 | 2024-09-17 | 江南大学 | 一类egfr别构抑制剂的合成及其用途 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US5266573A (en) | 1989-08-07 | 1993-11-30 | Elf Sanofi | Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| MX9707453A (es) | 1995-03-30 | 1997-12-31 | Pfizer | Derivados de quinazolina. |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
| ZA986732B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| SK288365B6 (sk) | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
| EE04748B1 (et) | 1999-06-21 | 2006-12-15 | Boehringer Ingelheim Pharma Kg | Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| ATE350378T1 (de) | 2000-04-08 | 2007-01-15 | Boehringer Ingelheim Pharma | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| DE10042061A1 (de) | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE60137273D1 (de) | 2000-10-20 | 2009-02-12 | Eisai R&D Man Co Ltd | Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten |
| DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| HUP0500117A3 (en) | 2001-11-30 | 2008-03-28 | Pfizer Prod Inc | Processes for the preparation of substituted quinazoline derivatives for the treatment of abnormal cell growth |
| JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| US7375134B2 (en) | 2002-03-05 | 2008-05-20 | Axys Pharmaceuticals, Inc. | Cathepsin cysteine protease inhibitors |
| DE10217689A1 (de) | 2002-04-19 | 2003-11-13 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| PE20040945A1 (es) | 2003-02-05 | 2004-12-14 | Warner Lambert Co | Preparacion de quinazolinas substituidas |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| AU2004272346A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
| CN1972688B (zh) | 2004-05-06 | 2012-06-27 | 沃尼尔·朗伯有限责任公司 | 4-苯胺基-喹唑啉-6-基-酰胺类化合物 |
| DK1789390T3 (da) | 2004-09-02 | 2012-02-27 | Genentech Inc | Pyridyl-inhibitorer af hedgehog-signalering |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| WO2007055513A1 (en) | 2005-11-08 | 2007-05-18 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof |
| CN101535279B (zh) | 2006-09-11 | 2015-05-20 | 柯瑞斯公司 | 含锌结合基的喹唑啉基egfr抑制剂 |
| TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| AU2008298948B2 (en) | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| WO2010036629A2 (en) | 2008-09-26 | 2010-04-01 | National Health Research Institutes | Fused multicyclic compounds as protein kinase inhibitors |
| WO2011084796A2 (en) * | 2009-12-21 | 2011-07-14 | Qiang Zhang | Novel quinazoline derivatives |
| CN102382106A (zh) | 2010-08-30 | 2012-03-21 | 黄振华 | 苯胺取代的喹唑啉衍生物 |
| CN102382065B (zh) | 2010-08-30 | 2014-05-28 | 山东轩竹医药科技有限公司 | 苯胺取代的喹唑啉衍生物 |
| CN102452989B (zh) | 2010-10-19 | 2014-10-22 | 山东轩竹医药科技有限公司 | 苯胺取代的喹唑啉衍生物 |
| BR112013022552B1 (pt) | 2011-03-04 | 2021-11-23 | Newgen Therapeutics, Inc | Compostos de quinazolina substituídos com alcino, seu uso, composição farmacêutica, e kit |
| CN102731485B (zh) * | 2011-04-02 | 2016-06-15 | 齐鲁制药有限公司 | 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途 |
| WO2013013640A1 (zh) | 2011-07-27 | 2013-01-31 | 上海医药集团股份有限公司 | 喹唑啉衍生物、其制备方法、中间体、组合物及其应用 |
| CN103987700B (zh) | 2012-03-09 | 2016-08-31 | 江苏豪森药业集团有限公司 | 4-喹唑啉胺类衍生物及其用途 |
| WO2013173254A1 (en) * | 2012-05-14 | 2013-11-21 | Dawei Zhang | Bicyclic compounds as kinases inhibitors |
| CN103965120B (zh) * | 2013-01-25 | 2016-08-17 | 上海医药集团股份有限公司 | 喹啉及喹唑啉衍生物、制备方法、中间体、组合物及应用 |
| WO2014177038A1 (en) * | 2013-04-28 | 2014-11-06 | Sunshine Lake Pharma Co., Ltd. | Aminoquinazoline derivatives and their salts and methods of use thereof |
| CN104513229A (zh) | 2013-09-28 | 2015-04-15 | 正大天晴药业集团股份有限公司 | 喹唑啉衍生物及其制备方法 |
| AU2014331794C1 (en) | 2013-10-10 | 2019-09-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C |
| WO2016023217A1 (zh) | 2014-08-15 | 2016-02-18 | 安润医药科技（苏州）有限公司 | 喹唑啉衍生物、其制备方法、药物组合物和应用 |
| WO2016055982A1 (en) * | 2014-10-10 | 2016-04-14 | Acerta Pharma B.V. | Quinoline and quinazoline compounds |
| AU2019346550A1 (en) | 2018-09-25 | 2021-04-22 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use |
-
2019
- 2019-09-24 AU AU2019346550A patent/AU2019346550A1/en not_active Abandoned
- 2019-09-24 JP JP2021540390A patent/JP2022502495A/ja active Pending
- 2019-09-24 EP EP19783859.2A patent/EP3856726A1/en not_active Withdrawn
- 2019-09-24 MX MX2021003517A patent/MX2021003517A/es unknown
- 2019-09-24 KR KR1020217011604A patent/KR20210137422A/ko not_active Ceased
- 2019-09-24 CN CN201980077292.XA patent/CN113382986A/zh active Pending
- 2019-09-24 WO PCT/US2019/052784 patent/WO2020068867A1/en not_active Ceased
- 2019-09-24 CA CA3113241A patent/CA3113241A1/en active Pending
- 2019-09-24 SG SG11202102981SA patent/SG11202102981SA/en unknown
- 2019-09-24 BR BR112021005513-4A patent/BR112021005513A2/pt not_active IP Right Cessation
-
2020
- 2020-04-17 US US16/851,767 patent/US11034672B1/en active Active
-
2021
- 2021-03-12 US US17/200,743 patent/US20220363666A1/en not_active Abandoned
- 2021-03-25 IL IL281805A patent/IL281805A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022502495A5 (https=) | ||
| JPWO2020068867A5 (https=) | ||
| JP7592689B2 (ja) | Ｓｔｉｎｇアゴニストとしての大環状化合物並びにその方法及び使用 | |
| US11034672B1 (en) | Tyrosine kinase inhibitor compositions, methods of making and methods of use | |
| CN106068262B (zh) | 喹唑啉衍生物及其制备方法和在医药上的应用 | |
| CN101678029A (zh) | 基于嘌呤的cdk抑制剂与酪氨酸激酶抑制剂的组合及其在治疗增生性疾病中的用途 | |
| JP2024114976A (ja) | がんの処置のための併用療法 | |
| ES2360933T3 (es) | Derivados de heteroarilo condensados. | |
| JP2022537772A (ja) | 新規ｅｇｆｒ阻害剤 | |
| JP2023123854A5 (https=) | ||
| JP2022538403A (ja) | がんの治療のためのｅｇｆｒ阻害剤 | |
| KR20230121756A (ko) | Fgfr 억제제 및 이의 제조 및 사용 방법 | |
| WO2020027083A1 (ja) | キナゾリン化合物を有効成分とする医薬組成物 | |
| US20140161722A1 (en) | Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members | |
| JPWO2019139899A5 (https=) | ||
| US20230233557A1 (en) | Formulations comprising heterocyclic protein kinase inhibitors | |
| JP2012510444A (ja) | 治療的処置のためのＨｓｐ９０阻害剤 | |
| JP2017521474A5 (https=) | ||
| CN103002899A (zh) | 作为pi3k抑制剂用于治疗抗增殖障碍的哌嗪子基三嗪化合物 | |
| CN103476769A (zh) | 新型抗癌剂 | |
| JP2008501708A (ja) | がんの治療方法 | |
| JP7289961B1 (ja) | がん治療のための併用療法 | |
| JP6553726B2 (ja) | 腫瘍治療剤 | |
| WO2025152908A1 (zh) | 氨基杂芳基大环化合物及其制备方法和应用 | |
| EA049394B1 (ru) | Ингибиторы fgfr и способы их получения и применения |